Date: Wed, 2 Nov 94 16:35:21 EST From: Bob Broedel To: Stuart.Neilson@brunel.ac.uk Subject: Re: ALS Interest Group List =============================================================== == == == ----------- ALS Interest Group ----------- == == ALS Digest (#128, 26 September 1994) == == == == ------ Amyotrophic Lateral Sclerosis (ALS) == == ------ Motor Neurone Disease (MND) == == ------ Lou Gehrig's disease == == ----- == == This e-mail list has been set up to serve the world-wide == == ALS community. That is, ALS patients, ALS researchers, == == ALS support/discussion groups, ALS clinics, etc. Others == == are welcome (and invited) to join. The ALS Digest is == == published (approximately) weekly. Currently there are == == 350+ subscribers. == == == == To subscribe, to unsubscribe, to contribute notes, == == etc. to ALS Digest, please send e-mail to: == == bro@huey.met.fsu.edu (Bob Broedel) == == Sorry, but this is *not* a LISTSERV setup. == == == == Bob Broedel; P.O. Box 20049; Tallahassee, FL 32316 USA == =============================================================== CONTENTS OF THIS ISSUE: 1 .. Organo-P and MND 2 .. speech aids 3 .. NEURONTIN TRIAL PLANNED 4 .. postdoctoral fellow in Developmental 5 .. Physical Medicine and Rehabilitation 6 .. Regeneron/neurotrophic factors (1) ===== Organo-P and MND ========== Topic 532 Organo-P and MND bionet.neuroscience 10:23 PM Sep 16, 1994 >from: loldfield@cix.compulink.co.uk Sorry if this is not in exactly the right place. A friend of mine has been led to believe that there may be a connection between exposure to organo-phosphorus compounds and motor neuron disease. I have no idea, does anyone else please? [I don't think we are talking about DNA here BTW ;-)], Thanks, Leigh. (2) ===== speech aids ========== >From : SadieJanie@aol.com X-Mailer: America Online Mailer Date : Wed, 21 Sep 94 23:25:56 EDT Subject : speech aids Thanks to all who have offered information on speech aids. We are at a point with my mother in law where this information will be very useful to us to enable her to communicate better. Also, I pass on all the positive information I read in the ALS digests and communications to her to let her know she's not alone and to offer her peace of mind in knowing that there are different tools available to help keep her in the mainstream of life. Thanks and God Bless. (3) ===== NEURONTIN TRIAL PLANNED ========== NEURONTIN TRIAL PLANNED. There are plans to conduct a seven center/150 patient double-blind, placebo controlled study of neurontin as a potential therapy for ALS. Principal investigator of the study, sponsored by ParkeDavis, is Dr. Robert Miller at California Pacific Medical Center. Application has been made to the FDA. Pending approval for the Phase II trial, it is hoped the study can begin by the end of September. For further information about participation in the trial, contact one of the following centers. Forbes Norris ALS Research Center; California Pacific Medical Center; 3698 California Street; San Francisco CA 94118. TEL 415-750-6040. Robert G. Miller, MD, Deborah F. Gelinas MD. University of Colorado Health Sciences Center; 4200 East Ninth Avenue; Denver CO 80262. TEL 303-270-7046 or 270-7211. Stephen P. Ringel, MD, James R. Murphy, MD, Hans E. Neville, MD. University of Minnesota Hospital & Clinic; 420 Delaware SE, Box 295; Minneapolis MN 55455. TEL 612-626-4107. Gareth J. Parry, MD. University of Utah; 50 N. Medical Drive; Salt Lake City UT 84132. TEL 801-581-8916. Jack Patajan, MD. University of Iowa Hospitals; 2 RCP; Iowa City IA 52242. TEL 317-365-2065. Mark Ross, MD. University of Texas Health Sciences Center; 5253 Harry Hines Blvd.; Dallas TX 75235. TEL 214-688-6419. Wilson Dryan, MD. Loma Linda University Medical Center; 11235 Anderson Street, Room 1580; Loma Linda CA 92354. TEL 909-824-4907. Carmen Armon, MD. ==== = This information taken from the monthly periodical SHARING: Information = Specifically for ALS Association Support Group Leaders (September 1994). = This information (and much more about IGF-1, Riluzole, etc.) will soon = be published in the periodical LINK (Fall 1994 issue). I strongly = suggest that all readers of this e-mail network subscribe to LINK = because it an important source for information about ALS. = = LINK; The ALS Association; 21021 Ventura Bouldvard, Suite 321; Woodland = Hills CA 91364. TEL 818-340-7500 FAX 818-340-2060 = Patient Hot Line: 800-782-4747 ==== (4) ===== Postdoctoral fellow in Developmental ========== Topic 534 Postdoctoral fellow in Developmental bionet.neuroscience 10:41 AM Sep 20, 1994 >From: iah211@eccles.anu.edu.au A position is available in the Developmental Neurobiology Group within the Division of Neuroscience, in the John Curtin School of Medical Research, Australian National University. This group researches the developmental processes that are essential for establishing correct connectivity of the nervous and the application of this knowledge in assisting regeneration after nerve damage. The research uses immunological, molecular biological, biochemical and histochemical techniques to study the roles of neurotrophic factors and their second messenger molecules. The specific aims of the research over the next three years will be to identify which second messenger molecules are involved in the neurite outgrowth and neurone survival response to a variety of neurotrophic factors. The successful applicant must have a PhD and appropriate experience in the areas of neurotrophin or second messenger biochemistry. Enquires should be addressed to the head of the group (Dr. Ian Hendry) phone 062494780, FAX 062492687, E-mail Ian.Hendry@anu.edu.au. Closing date 14 October 1994 (5) ===== Physical Medicine and Rehabilitation ========== Date : Thu, 22 Sep 1994 09:01:07 CDT Sender : NEW-LIST - New List Announcements >From : Bob Moore Subject: NEW: REHAB-RU - Physical Medicine and Rehabilitation REHAB-RU on LISTSERV@UKCC Physical Medicine and Rehabilitation or LISTSERV@UKCC.UKY.EDU Physical medicine and rehabilitation, especially in rural and community settings, is the topic of the REHAB-RU list. The list is unmoderated and open to all who wish to share ideas, opinions, inquiries, and information related to the topic. The REHAB-RU list is provided by the Department of Physical Medicine and Rehabilitation at the University of Kentucky, Lexington, KY, USA, which serves a large population in Appalachia and other rural areas of our region. By default all information posted to REHAB-RU is in the public domain unless the author attaches a copyright notice. Archives of REHAB-RU mail items are kept in monthly files. You may obtain a list files in the archives by sending the command INDEX REHAB-RU in the BODY of e-mail to LISTSERV@ukcc on BITNET or to LISTSERV@ukcc.uky.edu on the Internet. To subscribe to REHAB-RU, send the following command to LISTSERV@ukcc or LISTSERV@ukcc.uky.edu in the BODY of e-mail: SUBSCRIBE REHAB-RU Yourfirstname Yourlastname For example: SUBSCRIBE REHAB-RU John Doe Owner: Robert W. Moore STR002@ukcc.uky.edu (6) ===== Regeneron/neurotrophic factors ========== REGENERON BROADENS ITS INTELLECTUAL PROPERTY RIGHTS; RECEIVES TWO NEW U.S. PATENTS COVERING 2ND GENERATION NEUROTROPHIC FACTORS; SIGNS WORLDWIDE TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sept. 21, 1994--Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced that it has enhanced its intellectual property portfolio as a result of issuance of two U.S. patents covering second-generation neurotrophic factors and the recent execution of a license agreement covering neurotrophin-3. United States Patent No. 5,349,056 covering second-generation ciliary neurotrophic factor (CNTF), and United States Patent No. 5,349,055 covering second-generation nerve growth factor (NGF) were issued to Regeneron yesterday by the United States Patent and Trademark Office. Second-generation CNTF, named Axokine(TM), has higher potency than CNTF and is currently under preclinical development at Regeneron. The second-generation NGF technology was developed in collaboration with the late Dr. Hakan Persson and Dr. Carlos Ibanez of the Karolinska Institute, and Regeneron is the exclusive licensee of the technology. Regeneron has received a co-exclusive license to neurotrophin-3 (NT-3) as a result of a worldwide licensing agreement between Amgen Inc., Regeneron, Takeda Chemical Industries Ltd. and Genentech Inc. NT-3 is a naturally occurring trophic protein important for the survival and maintenance of sensory nerves, which are responsible for transmitting impulses from the receptors in the muscles, joints, skin and other sense organs. Amgen recently submitted an Investigational New Drug application to the Food and Drug Administration to initiate human clinical trials of NT-3 on behalf of Amgen-Regeneron Partners for the treatment of peripheral neuropathy. The newly issued patents apply to second-generation neurotrophic factors that are related to CNTF and NGF. A recent publication in the Aug. 19, 1994 edition of Science described the arrest of motor neuron disease in Wobbler mice cotreated with CNTF and BDNF ==================== for four weeks. The two nerve growth factors each promote the survival and differentiation of developing motor neurons by distinct cellular signaling pathways, and are thought to act synergistically when coadministered. It is hoped that similar effects will be observed in preclinical trials of second-generation CNTF (Axokine(TM)) in combination with BDNF. Regeneron (NASDAQ:REGN) is a leader in the discovery and development of biotechnology-based compounds for the treatment of neurodegenerative diseases, peripheral neuropathies and nerve injuries. CONTACT: Regeneron Pharmaceuticals Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6707 Selena Chaisson or Gail Kempler TEL 914-347-7000 FAX 914-347-2113/914-347-2815 == end of als 128 ==